MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, KURA had $13,339K increase in cash & cash equivalents over the period. -$83,194K in free cash flow.

Cash Flow Overview

Change in Cash
$13,339K
Free Cash flow
-$83,194K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-74,116 -123,551
Share-based compensation expense
10,965 14,791
Depreciation expense
164 465
Non-cash interest expense
141 271
Amortization of premium and accretion of discounts on short-term investments, net
1,924 5,182
Contract liabilities
15,664 23,763
Accounts payable and accrued expenses
12,716 2,098
Other long-term liabilities
297 628
Receivable from contracts with collaborators
31,362 2,514
Prepaid expenses and other current assets
10,289 8,551
Operating lease right-of-use and other long-term assets
2,883 2,922
Net cash used in operating activities
-80,627 -100,704
Maturities of short-term investments
235,032 342,596
Purchases of short-term investments
138,499 383,314
Purchases of property and equipment
2,567 1,750
Net cash provided by (used in) investing activities
93,966 -42,468
Proceeds from issuance of stock under equity plans
0 658
Net cash provided by financing activities
0 658
Net increase (decrease) in cash and cash equivalents
13,339 -142,514
Cash and cash equivalents at beginning of period
224,462 -
Cash and cash equivalents at end of period
95,287 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Kura Oncology, Inc. (KURA)

Kura Oncology, Inc. (KURA)